51. Change in neutrophil to lymphocyte ratio (NLR) as a predictor of treatment failure in renal cell carcinoma patients: Analysis of the IROC (Investigating RCC Outcomes) cohort
- Author
-
Vadim S. Koshkin, Rohan Garje, Mollie R. De Shazo, Arpita Desai, Yash Suri, Yousef Zakharia, Audrey Phone, Patrick Sweeney, Tristan Bice, Lakshminarayanan Nandagopal, Deepak Kilari, Arnab Basu, Luna Acharya, Pedro C. Barata, and Abigail Chan
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,fungi ,medicine.disease ,Treatment failure ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,030220 oncology & carcinogenesis ,Internal medicine ,Cohort ,Medicine ,Neutrophil to lymphocyte ratio ,business ,030215 immunology - Abstract
344 Background: IROC is an expanding multi-institution collaborative database which includes socioeconomic, genomic, pathologic, clinical and laboratory data in metastatic RCC patients (pts), primarily in the modern setting. Elevated baseline NLR is now an established poor prognostic factor in renal cell carcinoma (RCC) but currently has limited practical use. We hypothesized that an increase in NLR of 3 or more (NLR Failure) at 2 months on therapy could be a predictor of eventual treatment failure and shorter overall survival and thus augment the utility of this marker. Methods: Patients with complete data on NLR at time = 0 and +2 months of therapy were analyzed. Information on comorbidities, previous therapy, demographics were collected for adjusted analysis. NLR failure was defined as an increase of 3 or more compared to baseline NLR. Cox proportional hazard models were used to analyze the risk of progression and death with NLR failure at 2 months (+/- 2 weeks). Kaplan Meier graphs were constructed to trace survival functions for PFS and OS by NLR. Results: Among 165 pts; 121 were eligible (Table). NLR failure at 2 months was associated with a highly statistically significant increase in the risk of death in < 1 year (HR 6.82, 95% CI [3.16-14.70], p
- Published
- 2021